Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role.
Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at ScholarRock.com and follow @ScholarRock and on LinkedIn.
Summary of Position:
The Director of Development Sciences is a key position in our Clinical Development Group that will help drive the next phase of Scholar Rock’s growth with energy and dedication. This candidate will provide scientific leadership, accountable for driving strategy and decision-making in collaboration with other functions by ensuring relevant information, analysis, and expertise are considered. This position requires a highly organized and collaborative and adept clinical scientist with strong critical thinking skills, attention to detail, and agility. The position is focused on specific therapeutic areas, with responsibilities across stages of clinical development from phase 1 through phase 3.